98 related articles for article (PubMed ID: 11233992)
1. Effects of vasoactive intestinal peptide (VIP) and somatostatin (SST) on lipoprotein receptor expression by A431 tumor cells.
Li SR; Koller E; Valent P; Gludovacz D; Yang Q; Patri P; Angelberger P; Dudczak R; Virgolini I
Life Sci; 2001 Feb; 68(11):1243-57. PubMed ID: 11233992
[TBL] [Abstract][Full Text] [Related]
2. Cross-competition between vasoactive intestinal peptide and somatostatin for binding to tumor cell membrane receptors.
Virgolini I; Yang Q; Li S; Angelberger P; Neuhold N; Niederle B; Scheithauer W; Valent P
Cancer Res; 1994 Feb; 54(3):690-700. PubMed ID: 7905785
[TBL] [Abstract][Full Text] [Related]
3. Comparison of expression and regulation of the high-density lipoprotein receptor SR-BI and the low-density lipoprotein receptor in human adrenocortical carcinoma NCI-H295 cells.
Martin G; Pilon A; Albert C; Vallé M; Hum DW; Fruchart JC; Najib J; Clavey V; Staels B
Eur J Biochem; 1999 Apr; 261(2):481-91. PubMed ID: 10215860
[TBL] [Abstract][Full Text] [Related]
4. Somatostatin inhibits vasoactive intestinal peptide-stimulated cyclic adenosine monophosphate accumulation in GH pituitary cells.
Dorflinger LJ; Schonbrunn A
Endocrinology; 1983 Nov; 113(5):1541-50. PubMed ID: 6194974
[TBL] [Abstract][Full Text] [Related]
5. Structural peculiarities of the binding of very low density lipoproteins and low density lipoproteins to the LDL receptor in hypertriglyceridemia: role of apolipoprotein E.
Dergunov AD; Smirnova EA; Merched A; Visvikis S; Siest G; Yakushkin VV; Tsibulsky V
Biochim Biophys Acta; 2000 Feb; 1484(1):29-40. PubMed ID: 10685028
[TBL] [Abstract][Full Text] [Related]
6. Regulation by vasoactive intestinal peptide, histamine, somatostatin-14 and -28 of cyclic adenosine monophosphate levels in gastric glands isolated from the guinea pig fundus or antrum.
Gespach C; Hui Bon Hoa D; Rosselin G
Endocrinology; 1983 May; 112(5):1597-606. PubMed ID: 6131813
[TBL] [Abstract][Full Text] [Related]
7. Mode of action of somatostatin to inhibit secretion by shark rectal gland.
Silva P; Stoff JS; Leone DR; Epstein FH
Am J Physiol; 1985 Sep; 249(3 Pt 2):R329-34. PubMed ID: 2863985
[TBL] [Abstract][Full Text] [Related]
8. Lack of evidence for cross-competition between vasoactive intestinal peptide and somatostatin at their respective receptors.
Hannon JP; Langenegger D; Waser B; Hoyer D; Reubi JC
Eur J Pharmacol; 2001 Aug; 426(3):165-73. PubMed ID: 11527540
[TBL] [Abstract][Full Text] [Related]
9. Characterization of LDL and VLDL binding sites on human basophils and mast cells.
Virgolini I; Li SR; Yang Q; Koller E; Sperr WR; Leimer M; Angelberger P; Nimpf J; Schneider W; Valent P
Arterioscler Thromb Vasc Biol; 1995 Jan; 15(1):17-26. PubMed ID: 7538422
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin inhibits basal and vasoactive intestinal peptide-stimulated hormone release by different mechanisms in GH pituitary cells.
Dorflinger LJ; Schonbrunn A
Endocrinology; 1983 Nov; 113(5):1551-8. PubMed ID: 6138245
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein-associated alpha-tocopheryl-succinate inhibits cell growth and induces apoptosis in human MCF-7 and HBL-100 breast cancer cells.
Pussinen PJ; Lindner H; Glatter O; Reicher H; Kostner GM; Wintersperger A; Malle E; Sattler W
Biochim Biophys Acta; 2000 May; 1485(2-3):129-44. PubMed ID: 10832094
[TBL] [Abstract][Full Text] [Related]
12. Very low density lipoprotein binding to cultured aortic endothelium.
Desai KS; Gotlieb AI; Steiner G
Can J Physiol Pharmacol; 1985 Jul; 63(7):809-15. PubMed ID: 4042016
[TBL] [Abstract][Full Text] [Related]
13. Interaction of serum lipoproteins with the intestine. Evidence for specific high density lipoprotein-binding sites on isolated rat intestinal mucosal cells.
Suzuki N; Fidge N; Nestel P; Yin J
J Lipid Res; 1983 Mar; 24(3):253-64. PubMed ID: 6842082
[TBL] [Abstract][Full Text] [Related]
14. Characterization and specificity of lipoprotein binding to term human placental membranes.
Naoum HG; De Chazal RC; Eaton BM; Contractor SF
Biochim Biophys Acta; 1987 Aug; 902(2):193-9. PubMed ID: 3620456
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of VIP-stimulated intestinal secretion and cyclic AMP production by somatostatin in the rat.
Carter RF; Bitar KN; Zfass AM; Makhlouf GM
Gastroenterology; 1978 Apr; 74(4):726-30. PubMed ID: 204536
[TBL] [Abstract][Full Text] [Related]
16. A human melanoma-derived cell line (IGR39) with a very high number of vasoactive-intestinal-peptide (VIP) receptors. 2. Effect of VIP on cAMP production and on cell-surface VIP-binding sites.
Martin JM; Luis J; Marvaldi J; Pichon J; Pic P
Eur J Biochem; 1989 Mar; 180(2):435-9. PubMed ID: 2538331
[TBL] [Abstract][Full Text] [Related]
17. Vasoactive intestinal peptide (VIP) inhibits substrate adherence capacity of rat peritoneal macrophages by a mechanism that involves cAMP.
Segura JJ; Guerrero JM; López-Gonzalez MA; Calvo JR
Cell Adhes Commun; 1993 Dec; 1(3):213-21. PubMed ID: 7521755
[TBL] [Abstract][Full Text] [Related]
18. Expression of different lipoprotein receptors in natural killer cells and their effect on natural killer proliferative and cytotoxic activity.
De Sanctis JB; Blanca I; Bianco NE
Immunology; 1995 Nov; 86(3):399-407. PubMed ID: 8550077
[TBL] [Abstract][Full Text] [Related]
19. Studies on the binding and degradation of human very-low-density lipoproteins by human hepatoma cell line HepG2.
Dashti N; Wolfbauer G
Biochim Biophys Acta; 1986 Feb; 875(3):473-86. PubMed ID: 3004589
[TBL] [Abstract][Full Text] [Related]
20. Receptors for VIP and PACAP in guinea pig cerebral cortex: effects on cyclic AMP synthesis and characterization by 125I-VIP binding.
Zawilska JB; Dejda A; Niewiadomski P; Gozes I; Nowak JZ
J Mol Neurosci; 2005; 25(3):215-24. PubMed ID: 15800375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
